Although it has done damage to Race, it sounds like it may have contributed significantly to there being an opportunity for Race to exploit. If it wasn't buried then someone else may have looked at bisantrene sooner.
What does it say about the ethics of both the company (perhaps not unexpected) and the publication (more surprising) to produce and approve a paper with an intentionally misleading abstract? I thought the point of the peer review process was to make sure things like this don't happen.
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-104
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |